RxDoctor Payments Data

Kathleen Yang, MD

Gynecologic Oncology · Eugene, ORNPI 1902931587

Payments from drug & device makers

What this record shows

Almost everything reported here is food and beverage — 92.4% of the total across 17 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. 6 manufacturers reported payments, led by Intuitive Surgical at 51.1% of the total. Reporting peaked in 2022 at $536 and has fallen 75.2% since, to $133 in 2025. That places this record below the midpoint for gynecologic oncology clinicians in OR, where the typical reported total is $3,009.

$1,081in general payments, 2019–2025

Across 17 payments — averaging $63.57 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Intuitive Surgical$552
  • GSK$200
  • Gen-probe Sales & Service, Inc.$122
  • Myriad Genetic Laboratories, Inc.$102
  • Baxter Healthcare$78
  • AstraZeneca$26

What the payments were for

  • Food & beverage$99892%
  • Education$262%
  • Gifts$565%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
22
23
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Intuitive Surgical10$552
GSK2$200
Gen-probe Sales & Service, Inc.1$122
Myriad Genetic Laboratories, Inc.1$102
Baxter Healthcare2$78
AstraZeneca1$26

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,081 in reported general payments places this provider in the 20th percentile of 25 gynecologic oncology providers in Oregon.

See all gynecologic oncology providers in Oregon

Medicare billing

Part B allowed, 2024
$497,477
Medicare patients
242
Services billed
34,271

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban36$20,787
Dexamethasone29$797
Anastrozole22$718
Ondansetron Hcl34$716
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen74$448
Prochlorperazine Maleate31$316
Oxycodone Hcl19$122
Olanzapine21$36

Paid to pharmacies, not to this prescriber.

Other gynecologic oncology in Eugene

See the full list for Oregon

Where these figures come from

Is this you, or does something look wrong? →